SRC and ERK cooperatively phosphorylate DLC1 and attenuate its Rho-GAP and tumor suppressor functions

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• SRC and ERK kinases are key regulators of cell processes involved in tumorigenesis.
• DLC1 is a focal adhesion protein and tumor suppressor whose function is critical in cancer development.

Purpose of the Study:

• To investigate the physiological interaction between DLC1, SRC, and ERK kinases.
• To understand how SRC and ERK signaling pathways affect DLC1's tumor suppressor functions.

Main Methods:

• Identifying protein-protein interactions between DLC1, SRC, and ERK.
• Phosphorylation site analysis of DLC1 by SRC and ERK.
• In vivo studies using cancer models to assess the efficacy of kinase inhibitors.

Main Results:

• SRC phosphorylates DLC1 at Y451 and Y701, reducing its tumor suppressor activity.
• ERK1/2 phosphorylates DLC1 at S129, enhancing SRC binding and phosphorylation.
• SRC inhibitors demonstrated significant antitumor activity in DLC1-positive cancer models.
• Combined SRC and AKT inhibition showed enhanced antitumor effects.

Conclusions:

• SRC, ERK1/2, and AKT kinases cooperate to inhibit DLC1's Rho-GAP and tumor suppressor activities.
• Targeting these kinases with inhibitors can restore DLC1's tumor suppressor functions.
• Kinase inhibitors represent a potential therapeutic strategy for DLC1-positive cancers.